Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that data from
the Company’s oral, small molecule, complement C5 inhibitor program and
data from the Company’s global, Phase 2 clinical program evaluating
RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria
(PNH) will be presented at the 23rd Congress of the European
Hematology Association (EHA) from June 14-17, 2018 in Stockholm, Sweden.

Details of the oral presentation are as follows:

Title: Characterization of Orally Bioavailable Small Molecule
Inhibitors of Complement C5
Session Title: Bone marrow
failure syndromes incl. PNH – Biology & Translational Research
Presenter:
Alonso Ricardo, Ph.D., Senior Vice President and Head of Research, Ra
Pharma
Date/Time: Sunday, June 17, 8:15-8:30 CEST
Location:
Room A8
Abstract Code: 3854

Details of the poster presentation are as follows:

Title: RA101495, A Subcutaneously-administered Peptide Inhibitor
of Complement Component C5, For the Treatment of Paroxysmal Nocturnal
Hemoglobinuria: Phase 2 Results
Session Title: Bone marrow
failure syndromes incl. PNH – Clinical
Date/Time: Friday,
June 15, 17:30-19:00 CEST
Location: Poster area
Abstract
Code:
1430

About Ra Pharmaceuticals

Ra Pharmaceuticals is a clinical stage biopharmaceutical company
focusing on the development of next-generation therapeutics for
complement-mediated diseases. The Company discovers and develops
peptides and small molecules to target key components of the complement
cascade. For more information, please visit: www.rapharma.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the safety, efficacy
and regulatory and clinical progress of our product candidates,
including RA101495 SC, and statements regarding trial design, timeline
and enrollment of our ongoing and planned clinical programs. All such
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include the risks that Ra
Pharma’s product candidates, including RA101495 SC, will not
successfully be developed or commercialized; the risk that topline
results as of February 7, 2017 from the Company’s global Phase 2
clinical program evaluating RA101495 SC for the treatment of PNH may not
be indicative of final study results; as well as the other factors
discussed in the “Risk Factors” section in Ra Pharma’s most recently
filed Annual Report on Form 10-K, as well as other risks detailed in Ra
Pharma’s subsequent filings with the Securities and Exchange
Commission . There can be no assurance that the actual results or
developments anticipated by Ra Pharma will be realized or, even if
substantially realized, that they will have the expected consequences
to, or effects on, Ra Pharma. All information in this press release is
as of the date of the release, and Ra Pharma undertakes no duty to
update this information unless required by law.

Contacts

Investors:
Ra Pharmaceuticals, Inc.
Jennifer Robinson,
617-674-9873
jrobinson@rapharma.com
or
Media:
Argot
Partners
David Rosen, 212-600-1902
david.rosen@argotpartners.com